Condition: Advanced Solid Tumors · Sponsor: Sichuan Honghe Biotechnology Co., Ltd.
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
This description comes directly from the study's public registry record.
Zhao Manxi · 86 15882459305 · zhaomanqian@cnkh.com
Ziyun Gan · 86 15520826510 · 020735@cnkh.com
Always discuss trial participation with your own doctor first.
| Beijing Titan Hospital,Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05667194